Sweet Syndrome Following SARS-CoV2 Vaccination

Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-y...

Descripción completa

Detalles Bibliográficos
Autores principales: Baffa, Maria Efenesia, Maglie, Roberto, Giovannozzi, Neri, Montefusco, Francesca, Senatore, Stefano, Massi, Daniela, Antiga, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622799/
https://www.ncbi.nlm.nih.gov/pubmed/34835143
http://dx.doi.org/10.3390/vaccines9111212
Descripción
Sumario:Vaccines are today considered one of the most effective means against the Sars-CoV-2 pandemic. The BNT162b2 vaccine by Pfizer/BioNTech has been massively administered throughout the globe; since its approval, a wide spectrum of cutaneous reactions has been reported. Here we report the case of a 52-year-old Caucasian male who presented with an acute febrile eruption that arose 72 h after the first dose of the BNT162b2 vaccine. The clinicopathological findings were consistent with Sweet’s syndrome. The short latency time suggested a possible role of the vaccine in triggering Sweet’s syndrome in this case.

Ejemplares similares